Drug Trial Radar · NCT04429542
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
473
Planned (sponsor's estimate)
Start
Jun 1, 2020
Primary completion
Oct 31, 2027
Study completion Mar 30, 2028
Sponsor
- Lead sponsor
- Bicara TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Jun 12, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors.
Conditions
- Head and Neck Squamous Cell Carcinoma
- Squamous Cell Carcinoma of Anal Canal
- Colorectal Cancer
- Squamous Cell Carcinoma of the Lung
- EGFR Amplification
- Epithelial Ovarian Cancer
- Pancreas Cancer
- Cutaneous Squamous Cell Carcinoma
- Head and Neck Neoplasms
- Carcinoma, Squamous Cell
- Squamous Cell Carcinoma of Head and Neck
Interventions
BCA101Drug
EGFR/TGFβ fusion monoclonal antibody
PembrolizumabDrug
anti-PD-1
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of BCA101 alone and BCA101 in combination with pembrolizumab: Incidence and severity of AEs and SAEsTime frame: 24 months
- Tolerability of BCA101 alone and BCA101 in combination with pembrolizumab: Incidence and severity of AEs and SAEsTime frame: 24 months
- Incidence of Dose Limiting Toxicities (DLTs)Time frame: 21 days
Locations
21 sites in 3 countries. Site status is shown where the registry gives one.
Moores Cancer Center UC San Diego Health
La Jolla, California · Recruiting
Keck School of Medicine of USC
Los Angeles, California · Recruiting
UCLA
Los Angeles, California · Recruiting
University of California, Davis Comprehensive Cancer Center
Sacramento, California · Recruiting
H. Lee Moffitt Cancer Center and Research Institute, Inc
Tampa, Florida · Recruiting
Dana Farber/Partners Cancer Care Inc
Boston, Massachusetts · Recruiting
Memorial Sloan Kettering
New York, New York · Recruiting
Columbia University Herbert Irving Comprehensive Cancer Center
New York, New York · Recruiting
Levine Cancer Institute
Charlotte, North Carolina · Recruiting
Cleveland Clinic
Cleveland, Ohio · Recruiting
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania · Recruiting
Rhode Island Hospital
Providence, Rhode Island · Recruiting
Medical University of South Carolina, Hollings Cancer Center
Charleston, South Carolina · Recruiting
Vanderbilt University Medical Center
Nashville, Tennessee · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
Chris O'Brien Lifehouse
Camperdown, New South Wales, Australia · Recruiting
Calvary Mater Newcastle
Waratah, New South Wales, Australia · Recruiting
Austin Hospital
Heidelberg, Victoria, Australia · Recruiting
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia · Recruiting
Princess Margaret Cancer Centre
Toronto, Ontario, Canada · Recruiting
Centre hospitalier de l'Université de Montréal (CHUM)
Montreal, Quebec, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.